Business Wire

  1. Formulation And Delivery As The New Pharma Strategy 11/29/2011
    Confronted with a big patent expiration cycle this decade, and the lack of follow-on blockbusters, drug companies struggling for new sources of growth are turning towards new forms of innovative delivery technologies to sustain growth, according to a Lux Research report.
  2. West And Vetter Collaborate To Offer Customers An Innovative Filling Solution For Biopharmaceutical Drugs 11/3/2011
    West (NYSE: WST), a leading global manufacturer of components and systems for injectable drug delivery, and Vetter, a leading international independent specialist in the aseptic filling of drug-delivery systems, have collaborated to provide customers with the ability to source filled Daikyo Crystal Zenith(R) syringes.
  3. Acton Pharmaceuticals, Inc. Announces License Agreement With Sanofi U.S. For NASACORT HFA(TM) (triamcinolone acetonide) Nasal Aerosol 10/27/2011
    Acton Pharmaceuticals, Inc. (Acton), a specialty respiratory pharmaceutical company, announced today that it has completed a licensing agreement with Sanofi U.S. for prescription NASACORT HFA(TM) (triamcinolone acetonide) Nasal Aerosol for the treatment of nasal allergy symptoms.
  4. Bristol-Myers Squibb And Gilead Sciences Announce Licensing Agreement for Development And Commercialization Of New Fixed-Dose Combination Pill For People Living With HIV 10/27/2011
    Bristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences, Inc. (Nasdaq: GILD) today announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb’s protease inhibitor REYATAZ®(atazanavir sulfate) and Gilead’s cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.
  5. Approval Of US Pilot Clinical Trial To Evaluate AclarusDx™, The Exonhit Investigational Test For Alzheimer's Disease Diagnosis 10/27/2011
    Exonhit (Paris:ALEHT) announced today the Institutional Review Board (IRB) approval of Exonhit sponsored pilot clinical trial aimed at evaluating the performance of AclarusDx™, a blood based investigational diagnostic test, in US-based patients suffering from memory impairment and newly referred to a reference Memory Center for Alzheimer’s Disease (AD) diagnostic workup. This study will be conducted by the Cleveland Clinic Lou Ruvo Center for Brain Health.
  6. Alnylam Expands “Alnylam 5x15” RNAi Therapeutic Pipeline With ALN-APC, An RNAi Therapeutic Targeting Protein C For The Treatment Of Hemophilia 9/8/2011
    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has selected its fourth program in its ‘Alnylam 5x15’ initiative: ALN-APC, an RNAi therapeutic targeting protein C for the treatment of hemophilia. By reducing levels of protein C, a natural anticoagulant pathway, ALN-APC is intended to act by increasing thrombin generation and reducing the frequency of bleeding in hemophilia patients, including those more severe patients with inhibitors against their replacement factors.
  7. New Survey Finds Life Sciences Companies Struggling To Accurately Forecast Spending For Clinical Studies 8/1/2011
    ClearTrial recently announced the results of a new survey of life sciences professionals charged with forecasting and budgeting clinical studies at small, mid-sized, and Top 20 biopharmaceutical and medical device companies.
  8. Mirrx Therapeutics A/S Secures Seed Financing For Development Of Novel MicroRNA-Blocking Technology 2/4/2010
    Mirrx Therapeutics today announced that it has closed on a seed financing round that will enable the company to achieve in vivo proof of concept for its microRNA-blocking “Blockmir” technology, as well as to strengthen its intellectual property portfolio.
  9. Pfizer Announces Global Research Network 11/9/2009
    Pfizer Inc today announced its global research and development network, marking an important step in implementing a new R&D model as part of the integration of Pfizer and Wyeth.
  10. Pfizer And Private Access Announce Plans To Develop Online Community To Accelerate Clinical Research 8/20/2009
    Recognizing that patient participation in clinical trials is the key to progress in medical research, Pfizer Inc announced today that it has entered into a collaboration with Private Access, the innovator in privacy-enhanced search technology, to create a new online community aimed at increasing clinical trial awareness and participation.